Data has proved that there is high cure rate for cervical cancer proton therapy. In daily life, I hear that cervical erosion will become cancerous when it is severe. In fact, not all of them will become cancerous. It can only be said that patients with cervical erosion are at risk for kanker cervical. Cervical erosion can be cured by active treatment Yes, it ’s just that women often delay treatment, don’t take this disease seriously, and eventually make more serious diseases appear. Misconceptions about cervical cancer are often the key points that lead to the onset of the disease. importance.
Kajadian kanker serviks raket patalina sareng virus anu disebat manusa papilloma (HPV). Panilitian nunjukkeun yén inféksi kontinyu sareng jinis résiko tinggi papillomavirus manusa mangrupikeun faktor anu diperyogikeun pikeun timbulna kanker serviks sareng lesi anu sateuacanna. Virus tiasa dideteksi di seueur jalma anu penderita kanker serviks.
Sadaya awéwé anu hubungan séks tiasa katépaan ku Virus HPV ngaliwatan kontak séks. Sakitar 80% awéwé parantos katépaan ku virus dina kahirupan aranjeunna.
Tapi, kainfeksi HPV henteu merta ngakibatkeun kanker serviks, sabab unggal awéwé séhat ngagaduhan sababaraha kekebalan dina awakna. Panalitiyan negeskeun yén kalolobaan sistem imun awéwé tiasa mupus HPV anu asup kana awak saatos kainfeksi HPV. Ngan sababaraha awéwé anu henteu tiasa ngancurkeun HPV anu asup kana awak, nyababkeun inféksi HPV anu terus-terusan, anu tiasa nyababkeun kanker serviks. Sababaraha pasién ieu bakal maju ka kanker serviks, prosés anu peryogi sakitar 5 dugi ka 10 taun.
Naha HPV maju kana kanker serviks ogé aya hubunganana sareng jinis HPV. Aya sakitar 100 subtipe virus HPV. Jinis HPV anu paling umum dina inféksi saluran réproduktif awéwé nyaéta jinis 6, 11, 16, sareng 18, anu HPV6 sareng HPV11 mangrupikeun jenis résiko rendah, sedengkeun HPV16 sareng 18 mangrupikeun jenis anu résiko tinggi. Panilitian kanker serviks ti nagara-nagara saalam dunya mendakan yén jinis HPV16 sareng HPV18 ngagaduhan tingkat inféksi pangluhurna di antara pasién kanker serviks.
Mitos 2: Erosi serviks tiasa janten kanker
Seueur awéwé gaduh salah paham sapertos anu aranjeunna pikir érosi serviks tiasa nyababkeun kanker serviks, sareng aranjeunna sieun pisan kana erosi serviks.
Sacara médis, épithium kolom dina jero saluran serviks awéwé ngagentos épitél skuamosa tina serviks. Nalika dokter mariksa éta, anjeunna mendakan yén kamacetan lokal tina serviks beureum, anu disebat "erosi serviks". Érosi sanés "rot" dina hartos anu sajati. Éta tiasa janten fisiologis. Dina aksi éstrogén, awéwé dina umur ngalahirkeun, épitél kolom dina jero saluran cervical tétéla, ngagentos epitel skuam serviks, sareng katingalina "erosif". Sareng "érosi" awéwé jarang sateuacan pubertas sareng ménopause kusabab tingkat éstrogén anu kawilang rendah dina awak.
Perhatoskeun yén érosi serviks ogé tiasa janten kaayaan radang anu umum. Kanker serviks mimiti mirip pisan sareng erosi serviks sareng gampang lieur. Kusabab kitu, upami erosi serviks dipendakan nalika pamariksaan gynecological, éta moal tiasa dianggap enteng, sareng sitologi sareng biopsi langkung diperyogikeun pikeun mastikeun diagnosis, nolak kamungkinan kanker serviks, sareng ngubaran leres-leres.
Salah paham 3: Pamariksaan ginekologis henteu dipeunteun
Tina inféksi virus HPV dugi ka kajadian sareng pamekaran kanker serviks, aya jalan alami anu bertahap, biasana salami 5 dugi 10 taun. Kusabab kitu, salami awéwé diayak pikeun kanker serviks sacara rutin, tiasa dimungkinkeun pikeun mendakan "mecenghulna" panyakit dina waktosna sareng maéhan éta dina pucukna. Ayeuna, saatos diubaran penderita kanker serviks tahap awal, tingkat salamet lima taun tiasa ngahontal 85% dugi ka 90%.
Women of childbearing age must not neglect to perform annual gynecological examinations, including cervical cytology tests such as Pap smears or liquid-based cytology (TCT) tests, are important methods to detect cervical precancerous lesions and cervical cancer. In particular, the following populations at risk of cervical cancer should not be taken lightly:
Jalma anu terus kaserang jinis résiko tinggi tina virus HPV, nyaéta anu positip pikeun HPV16 sareng HPV18 nalika diuji pikeun virus HPV;
Jalma anu ngagaduhan faktor kabiasaan seksual goréng, kaasup umur dini tina kahirupan séks, sababaraha pasangan séks, kaséhatan seksual anu goréng, sareng sajabana, bakal ningkatkeun résiko kanker serviks;
Mitos 4: "Petunjuk Leutik" Teu dipalire
Kanker serviks moal nyababkeun henteu ngarareunah pasién dina tahap awal, sareng sababaraha gejala gampang diémutan. Awéwé yuswa ngalahirkeun kedah diajar merhatoskeun "peringatan kasihatan" anu dikaluarkeun ku awakna. Kadang-kadang, sanaos aranjeunna ngan ukur "inpormasi", panginten aya bahaya anu disumputkeun.
Saatos deteksi mimiti, kanker serviks henteu saé teuing. Terapi proton is still hopefully curable. Proton therapy is actually accelerating positively charged protons through an accelerator to become very strong ionizing radiation. It enters the human body at a high speed and is guided by special-shaped equipment to eventually reach the tumor site. Because it is fast, the chance of interacting with normal tissues or cells in the body is extremely low. When it reaches a specific part of the tumor, the speed suddenly decreases And stop, release a lot of energy, this energy can kill cancer cells without causing damage to surrounding tissues and organs. Proton therapy can still effectively treat tumors while protecting these important organs or structural functions. This is in the conventional radiation It is impossible in treatment.
Saatos awéwé ngagaduhan pamahaman anu leres ngeunaan panyakit, naha éta erosi serviks atanapi kanker serviks, aranjeunna kedah nyandak sikep positip pikeun ngubaranana. Nalika aya erosi serviks, mimitina ngaleungitkeun kamungkinan kanyeri, teras ngarawatna leres. Saatos dirawat, éta bakal damang, sareng sakali anjeun ngagaduhan kanker serviks, anjeun bakal nampi pangobatan anu épéktip dina waktos anu pertama, kondisina bakal gancang dikontrol, sareng kaséhatan anjeun bakal kirang dirugikeun.
